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KESAN BUDESONIDE DAN 5-AZASITIDINA TERHADAP PARAS METILASI 
DNA PADA KEPULAUAN CpG DI PROMOTER KOLINA KINASE MANUSIA 
ALPHA (ckα) DAN BETA (ckβ) 
ABSTRAK 
Kolina kinase (CK) merupakan enzim yang pertama di dalam tapak jalan CDP-kolina 
untuk sintesis fosfatidilkolina, komponen utama fosfolipid membran. Dalam manusia, 
CK dikodkan oleh gen ckα dan ckβ yang menghasilkan tiga isoform protein yang 
dikenali sebagai CKα1, CKα2 dan CKβ. CKα terlibat dalam pembentukan tumor 
manakala CKβ telah dikaitkan dengan distrofi otot. Metilasi DNA ialah tanda epigenetik 
penting dalam pengawalaturan ekspresi gen.  Kajian ini melaporkan status metilasi ckα 
dan ckβ manusia pada kepulauan CpG selepas rawatan agen epigenetic (Budesonide dan 
5-azasitidina). Dalam analisis silico terungkap kepulauan CpG pada setiap promotor ckα 
dan ckβ melalui alat prediksi MethPrimer dan EMBOSS CpGPlot dan lima puluh 
sembilan dan enam puluh dua pengikat laman faktor transkripsi pada pulau CpG ckα dan 
ckβ, masing-masing melalui alat prediksi Mat Inspektor dan TFBIND. Status metilasi 
yang diramalkan pada kepulauan CpG telah dianalisa melalui rawatan epigenetik pada 
sel MCF-7. Tujuh kawasan daripada empat belas kawasan promoter kepulauan CpG 
telah berjaya diamplifikasikan dengan menghasilkan produk PCR pada saiz yang 
diharapkan. Tujuh kawasan ini disasarkan untuk analisis selanjutnya. MCF-7 telah 
dikultur dan dibahagikan kepada empat kumpulan, terdiri daripada dua kumpulan 
rawatan iaitu kumpulan rawatan budesonide (70 μM, 24 jam) dan kumpulan rawatan 5-
azasitidina (1 μM; 96 jam) dan dua kumpulan kawalan, iaitu kumpulan kawalan 
budesonide (1% DMSO; 24 jam) dan kumpulan kawalan 5-azacytidine (1% DMSO; 96 
xvi 
 
jam). DNA genom daripada semua kumpulan telah diekstrak selepas pengeraman 
mereka dengan ubat epigenetik. Fragmentasi DNA genom untuk semua kumpulan 
mendedahkan DNA telah difragmentasi dari 200 bp hingga 3000 bp. DNA 
terfragmentasi ini kemudiannya tertakluk kepada prosedur IP. Proses memperbanyak 
oleh IP telah berjaya dibuktikan melalui amplifikasi kawalan DNA dan pencernaan oleh 
NcoI dengan membandingkan intensiti band sebelum dan selepas IP. Amplifikasi tujuh 
kawasan pulau CpG selepas IP promotor ck mendedahkan kebanyakan produk PCR pada 
saiz yang dijangkakan, tetapi tidak konsisten dalam intensiti band dalam kawasan CpG 
yang berbeza oleh kumpulan yang sama dan dalam kalangan kumpulan. Daripada tujuh 
kawasan ini, kawasan ckα-2ndCpG-2, ckβ-3rdCpG-4 dan ckα-4thCpG-7 menunjukkan 
paras tinggi status metilasi selepas rawatan ubat budesonide, manakala kawasan ckβ-
1
st
CpG-1 dan ckβ-3rdCpG-4 menunjukkan paras rendah status metilasi selepas rawatan 
ubat 5-azasitidina. Walau bagaimanapun, analisis ini memerlukan penyiasatan lanjut, 
kerana hanya menganalisis tujuh dan bukannya empat belas kawasan CpG promoter ckα 
dan ckβ. Analisis semua empat belas kawasan pulau CpG promotor ckα dan ckβ boleh 
memberikan maklumat yang jelas mengenai status metilasi kepulauan CpG kedua-dua 
promoter ckα dan ckβ.  
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THE EFFECT OF BUDESONIDE AND 5-AZACYTIDINE ON LEVELS OF DNA 
METHYLATION AT THE CpG ISLANDS OF HUMAN CHOLINE KINASE 
ALPHA (ckα) AND BETA (ckβ) PROMOTER 
ABSTRACT  
Choline kinase (CK) is the first enzyme in the CDP-choline pathway for the synthesis of 
phosphotidylcholine, a major component of membrane phospholipid. In human, CK is 
encoded by ckα and ckβ genes which produce three protein isoforms known as CKα1, 
CKα2 and CKβ. CKα is involved in tumorigenesis while CKβ is associated with 
muscular dystrophy. DNA methylation is an important epigenetic mark in gene 
expression regulation. This study reports on the methylation status of human ckα and ckβ 
promoter CpG islands after treatment with epigenetic drugs (budesonide and 5-
azacytidine). In silico analyses revealed multiple putative CpG islands on each ckα and 
ckβ promoter through MethPrimer and EMBOSS CpGPlot prediction tools and fifty-
nine and sixty-two putative transcription factor binding sites on ckα and ckβ promoter 
CpG islands respectively through Mat Inspector and TFBIND prediction tools. The 
methylation status of predicted putative CpG islands were analysed through epigenetic 
drugs treatment on MCF-7 cell line. Seven regions of out fourteen regions of the 
promoter CpG islands were successfully amplified by producing PCR products at their 
expected sizes. These seven regions were targeted for further analysis. MCF-7 were 
cultured and divided into four groups, consisting of two treatment groups which were 
budesonide (methylating agent) treated group (70 µM; 24 hours) and 5-azacytidine 
(demethylating agent)group (1 µM; 96 hours)  and two control groups, which were 
budesonide control group (1% DMSO; 24 hours)  and 5-azacytidine control group (1% 
xviii 
 
DMSO; 96 hours). Genomic DNA from all groups was extracted following their 
respective incubation time with the epigenetic drugs. Fragmentation of the genomic 
DNA for all groups revealed fragmented DNA ranging from 200 bp to 3000 bp. These 
fragmented DNAs were then subjected to IP procedure. Enrichment process of the IP 
was successfully proven through control DNA amplification and digestion by NcoI by 
comparing the band intensity before and after IP. Amplification of seven ck promoter 
CpG island regions after IP revealed most PCR products at expected sizes, but there 
were inconsistency in band intensity within CpG regions of similar group and among the 
groups. Out of these seven regions, ckα-2ndCpG-2, ckβ-3rdCpG-4 and ckα-4thCpG-7 
regions showed higher level of methylation status after budesonide drug treatment, while 
ckβ-1stCpG-1 and ckβ-3rdCpG-4 regions showed lower level of methylation status after 
5-azacytidine drug treatment. However, this analysis warrants further investigation, 
since only seven instead of fourteen CpG regions of ckα and ckβ promoter were 
analysed. Analysis of all fourteen ckα and ckβ promoter CpG island regions could give 
clearer information on both ckα and ckβ promoter CpG island methylation status after 
the treatment of epigenetic drugs. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
1.1 Phospholipids  
Cell membranes are structures which form boundary layers between two cellular 
compartments and play an extraordinarily vital part in the metabolism of cells (O'Brien, 
1967). Most lipids on the membrane contain a phosphate group and they are known as 
phospholipids (Karp, 2004). Phospholipids are the major component of all cell 
membranes (Figure 1.1) and due to their amphiphilic structures (possess both 
hydrophilic and hydrophobic properties), they can form lipid bilayers. 
Most membrane phospholipids have a glycerol backbone, which is called 
phosphoglycerides (Karp, 2004). Membrane phosphoglycerides have an additional 
group attached to the phosphate, either choline, forming phosphatidylcholine (PC) or 
ethanolamine, forming phosphatidylethanolamine (PE) (Karp, 2004). PC is the most 
abundant phospholipid in mammalian cells, comprising 40–50% of total phospholipids 
(Vance, 2015). 
 
1.1.1 Phosphatidylcholine (PC) 
PC is known as lecithin (Kuan, et al., 2014) (Figure 1.2) and it is the most abundant 
membrane phospholipid (40–60%) in eukaryotic cells (Kent, 2005). PC accounts for a 
major portion of phospholipids compare to phosphatidylethanolamine (PE), 
phosphatidylserine (PS), phosphatidylinositol (PI), cardiolipin and sphingomyelin (SM) 
and thus plays important roles in structural maintenance of the phospholipid bilayer (Cui 
and Houweling, 2002; Wu et al., 2008; Gibellini and Smith, 2010). Phosphatidylcholine 
2 
 
and lysophosphatidylcholine are also major structural features of serum lipoproteins 
(Kent, 2005). Phosphatidylcholine is also involved in signal transduction, serving as a 
substrate or activator for phospholipases in signal transduction pathways. Implication of 
the phospholipid metabolites and derivatives in different mitogenic signaling pathways 
was extensively described as well (Kent, 2005; Cui and Houweling, 2002; Gallego-
Ortega et al., 2011). PC biosynthesis is also needed for normal to very low-density 
lipoprotein secretion from hepatocytes (Gibellini & Smith, 2010). It is well known that 
together with polyphosphoinositides (PI) and PE, PC is the second messenger and major 
source of the arachidonic acid (AA) and its eicosanoid metabolites released by agonist 
activation of phospholipase A (PLA) in a variety of cells (Exton, 1994). PC hydrolysis 
in response to agonists and phorbol ester mainly resulted from activation of a 
phospholipase D (PLD) yielding phosphatidic acid (PA), and that much of the DAG 
arises due to the action of phosphatidate phosphohydrolase (PAP) on PA (Exton, 1990; 
Shukla and Halenda, 1991; Bilk et al., 1993). Besides, PC might act as an autocoid to 
modulate cellular functions as it causes Ca
2+
 influx across the plasma membrane in 
intact cells (Putney, 1980; Billah and Anthes, 1990).  
 
1.2 Biosynthesis of Phosphatidylcholine 
PC can be synthesized de novo in all mammalian cells by two pathways, (i) the CDP-
choline pathway and (ii) the PE methylation pathway (Aoyama et al., 2004).  
Diacylglycerol is the precursor for PC (Kent, 1995). In yeast, diacylglycerol is less 
important in rapidly growing cells, where the CDP-diacylglycerol branch is the principal 
pathway for the biosynthesis of PC (Kent, 1995). In most eukaryotic cells, PC and PE  
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: The structure of a cell membrane. The cell membrane is composed of lipid 
bilayers and membrane proteins. The external surface of most membrane proteins, as 
well as a small number of the phospholipids contain short chains of sugars, making 
them glycoproteins and glycolipids (Karp, 2004) 
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Figure 1.2: Chemical structure of phosphatidylcholine. It incorporates choline as polar 
head group and is a glycerophospholipid which acts as common membrane lipid. It is 
the most abundant phospholipid required for the synthesis of membranes in eukaryotic 
cells (Lacal, 2005). 
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Figure 1.3: Two branches of Kennedy pathway: (i) CDP-ethanolamine pathway and (ii) 
CDP-choline pathway. First enzyme: ethanolamine kinase (EK), choline kinase (CK). 
Second enzyme: phosphoethanolamine cytidylyltransferase (ECT), phosphocholine 
cytidylyltransferase (CCT). Third enzyme: ethanolaminephosphotransferase (EPT), 
cholinephosphotransferase (CPT) (Gibellini and Smith, 2010). 
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are synthesized through aminoalcoholphosphotransferase reaction, which uses sn-1,2-
diacylglycerol and either novel high-energy intermediates CDP-choline (Kennedy 
pathway) or CDP-ethanolamine, respectively (Gibellini and Smith, 2010; Fagone and 
Jackowski, 2013). Hence, the two branches of the Kennedy pathway are often referred to 
as CDP-choline and CDP-ethanolamine pathway, respectively (Figure 1.3) (Gibellini 
and Smith, 2010). CDP-choline pathway also exists in some pathogenic bacterial 
systems (Sohlenkamp et al., 2003). However, this pathway is not utilized for PC 
biosynthesis in those bacteria such as the Gram-negative Haemophilus influenzae, 
Pseudomonas aeruginosa and the Gram-positive Streptococcus pneumoniae, because 
they do not have significant PC in their membrane components. Instead, they use this 
pathway for the synthesis of P-Cho. The P-Cho moiety is transferred most likely from 
CDP-choline to their cell surface polysaccharides. This P-Cho modification of cell 
surface constituents seems to be very vital for their survival in the host animals (Aoyama 
et al., 2004). 
 
1.2.1 CDP-Choline Pathway 
 
In most mammalian cells, PC is synthesized mainly via the CDP-choline Pathway (Cui 
and Vance, 1996). The Kennedy pathway enzymes are found ubiquitously in eukaryotes 
(Gibellini and Smith, 2010). Although Kennedy pathway is not found in bacteria, but 
some of its enzymatic components are found and used for the modification of 
phosphocholine in the components of cell surface (Gibellini and Smith, 2010). 
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At first, choline kinase (CK) catalyzes the choline phosphorylation to phosphocholine 
using a molecule of ATP and Mg2+ as cofactor (Figure 1.3) (Aoyama et al., 2004; 
Gibellini and Smith, 2010). Then, in the rate-limiting step of the Kennedy pathway, the 
phosphocholine cytidylyl transferase (CCT) uses phosphocholine and cytidine-5’-
triphosphate to form the high-energy donor CDP-choline with the release of 
pyrophosphate (Figure 1.3) (Gibellini and Smith, 2010). Cholinephosphotransferase 
(CPT) catalyzes the final reaction of the pathway, using CDP-choline and a lipid anchor 
such as DAG or alkyl-acylglycerol (AAG) to form PC and cytidine-5’-monophosphate 
as byproducts (Figure 1.3) (Aoyama et al., 2004; Gibellini and Smith, 2010). 
 
1.3 Choline Kinase (CK) 
CK is an enzyme that was discovered in 1953 (Wu and Vance, 2010) which catalyzes 
the phosphorylation of choline to phosphocholine with the consumption of one molecule 
of ATP in the presence of Mg2+ as cofactor. This enzyme is important for the 
biosynthesis of PC, a major phospholipid in eukaryotic membranes (Aoyama et al., 
2004; Gibellini and Smith, 201; Gallego-Ortega et al., 2011; Fagone and Jackowski, 
2013). In 1953, Wittenberg and Kornberg first reported the isolation and biochemical 
characterization of CK and they showed that the enzymatic activity is commonly 
distributed in different tissues, including liver, brain, kidney and internal mucosa 
(Fagone and Jackowski, 2013). Besides, generation of phosphocholine from CK activity 
has been mentioned as an important event in the growth factor-induced mitogenesis in 
fibroblasts (Ramirez de Molina et al., 2002). CK has also been found to cooperate with 
several mitogens (Ramirez de Molina et al., 2002). 
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1.3.1 Isoforms of Choline Kinase 
Two isoforms of ck gene, ckα1 and ckα2 were previously reported from rat liver cDNA 
library (Uchida, 1994). ckα 1 (50kDa, 435 amino acids ; NCBI accession number 
NP_997634) and ckα2 (52kDa, 453 amino acids ; NCBI accession number NP_001268) 
were shown to be derived from the identical gene (ckα) by an alternative splicing as 
amino acid sequence showed about 60% similarity between these two isoforms. These 
two isoforms are differing by the presence of an 18-residue insert in ckα2 (Aoyama et 
al., 2004). ckß was clearly shown to be the separate gene (ckß) product as reported by 
Aoyama et al., 1998 through the cloning of cDNA from rat kidney cDNA library. ckß 
could encode 45kDa protein of 394 amino acids (NCBI accession number NP_005189) 
(Aoyama et al., 1998; Gruber et al., 2012). 
 
Northern and western blots showed that mammalian ckα and ckß isoforms are 
ubiquitously expressed in different tissues (Gruber et al., 2012). There are proofs for 
different metabolic and biological functions between the two isoforms that has been 
reported before (Lacal, 2015). One of the differences between the isoforms is that ckα is 
essential for mouse embryo development while ckβ is non-essential for mouse embryo 
development (Lacal, 2015). However, there is no evidence that suggests a significant 
differential role between ckα1 and ckα2 (Lacal, 2015). A significantly high expression 
of ckα was detected in both testis and liver, whereas a high expression of ckβ was found 
in heart and liver (Aoyama et al., 2004). ckα is mainly  involved in cell growth and 
proliferation (Gallego-Ortega et al., 2009). On the other hand, other than having a role in 
phospholipid biosynthesis, ckß is also involved in muscle development (Kuan et al., 
2014). 
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1.4 Choline Kinase and Disease Development 
Over the years, CK has been discovered to be involved in many cases of uncontrolled 
cell proliferation and tumor growth (Lacal, 2015). The elevated PCho and tCho levels 
that have been detected in human cancers are caused by interplay between severals 
enzymes, which are at the core of choline metabolism (Glunde et al., 2011).  
 
Dual choline and ethanolamine kinase activity are display by both ckα 1 and ckα 2 
homodimers with a lower Km for choline, whereas the ckß homodimer essentially has 
ethanolamine kinase activity, and the ckα – ckß heterodimer has intermediate substrate 
specificity (Aoyama et al., 2002; Gallego-Ortega et al., 2009). The proportions of 
different homodimer and heterodimer populations are tissue-specific (Aoyama et al., 
2002), and research with knockout mice showed that ckα loss, but not ckß loss, is 
embryonically lethal (Sher et al., 2006; Wu et al., 2008). Although the activity of yeast 
choline kinase (CKI) can be upregulated by protein kinase A (PKA)-dependent 
phosphorylation at both Ser30 and Ser85, there has been only one report indicating that 
PKA-mediated phosphorylation partially regulates human CK (Wieprecht et al., 1994). 
Thus, the upregulation of CK activity in cancer seemingly results from an increase in 
CKα expression, which would lead to a higher proportion of CKα – CKα dimers in 
cancer cells and in turn a higher CK activity level than CKα – CKß heterodimers or CKß 
– CKß homodimers (Glunde et al., 2008). Besides, in another research paper, Kuan and 
his colleagues demonstrate the participation of the protein kinase C (PKC) signaling 
pathway in the regulation of ckβ gene transcription by Ets and GATA transcription 
factors. They postulate that phorbol-12-myristate-13-acetate (PMA) represses ckβ 
promoter activity through binding of Ets and GATA transcription factors via the 
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activation of PKC signaling pathway (Kuan et al., 2014). Overexpression of CKα has 
been reported in several human tumour-derived cell lines of several origins, as well as in 
biopsy samples of lung, colon and prostate carcinomas, among others, which were 
compared with matched normal tissue from the same patient (Gallego-Ortega et al., 
2009; de Molina et al., 2002; de Molina et al., 2007).   
 
Advanced histological tumour grade and negative estrogen receptor status in breast 
carcinoma correlated with the increased enzymatic activity and overexpression of CKα 
(de Molina et al., 2002), which is consistent with the elevated levels of PCho and tCho 
that are seen in breast cancers (Gribbestad et al., 1999). Conversely, no significant 
correlation was found with age, tumour size, progesterone receptor status, vascular 
invasion and histological tumour type, or with expression of p53, ERBB2 or Ki-67, in 
these breast tumours (de Molina et al., 2002). These clinical findings provide CKα as 
potential prognostic marker of some cancers, such as non-small-cell lung cancer 
suggesting that CKα expression and activity is directly associated with elevated cancer 
cell proliferation and malignancy (de Molina et al., 2007). CKα expression and activity 
levels have not yet been studied in metastases.  
 
A part from that, transcriptional control of the regulators of choline metabolism by 
factors related with cancer has been most clearly demonstrated for CK. For instance, in 
the liver, the binding of JUN to a distal activator protein 1 (AP1) element in the 
promoter region of CKα mediates its expression, suggesting a correlation between the 
function of AP1 in cell proliferation and transformation of CK (Aoyama et al., 2007). 
Besides, there is a close correlation that was observed between region of high total 
11 
 
choline-containing compounds (tCho) levels and hypoxia in vivo (Glunde et al., 2008), 
which was determined to be due to the regulation of CKα expression by the transcription 
factor hypoxia-inducible factor 1 (HIF1) (Glunde et al., 2008). A potential role for the 
proto-oncogene MYC was suggested in studies that showed increase levels of CK and 
PCho in Myc+/+ compared with Myc−/− rat fibroblasts (Morrish et al., 2009).  
 
Although there is significant sequence identity between ckα and ckß, evidence for 
different metabolic and biological functions has been reported. The most difference has 
been found in KO mice studies. CKβ is expressed at a higher level in hindlimb muscle, 
suggesting that this isoform has a specialized role in this tissue (Fagone and Jackowski, 
2013). Removal of CKα results in embryonic lethality as it is necessary for mouse 
embryo development (Wu et al., 2008). Conversely, CKß is dispensable for mouse 
embryo development and CKß KO mice are viable but acquire rostrocaudal muscular 
dystrophy (Sher et al., 2006) due to reduced PC biosynthesis and increased catabolism 
of PC (Wu et al., 2010). A similar disease has been found in humans correlate to 
mutations of the ckß gene (Mitsuhashi and Nishino., 2013). In humans, genetic 
mutations of the ckβ gene cause congenital muscular dystrophy (CMD), a heterogeneous 
group of inherited muscle diseases characterized clinically by muscle weakness and 
hypotonia in early infancy (Mitsuhashi et al., 2011).  
 
1.5 Epigenetics  
The way of genes being expressed are controls by the human genome that is composed 
of billions of sequence arrangements containing a bioinformatics code. This code is 
further dependent upon heritable non-static epigenetic organization of histone 
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scaffolding that surrounds the DNA and comprises the “epigenome” (Mazzio and 
Soliman, 2012). Epigenetic processes are vital for development and differentiation 
processes (Jaenisch and Bird, 2003). Epigenetic mechanisms also protect a DNA 
sequence against viral genomes that would hijack and change cellular functions 
(Jaenisch and Bird, 2003). DNA methylation, RNA-associated silencing and histone 
modification are three systems used to initiate and sustain epigenetic silencing. 
Unravelling the correlation between these components has led to surprising and rapidly 
evolving new concepts, showing how they interact and stabilize each other (Egger et al., 
2004) (Figure 1.4). 
 
1.5.1 DNA Methylation 
DNA methylation is found exclusively at cytosine residues in eukaryotes ranging from 
plants to humans. It involves the addition of a methyl group to the carbon at position 5 
of the cytosine ring by DNA methyltransferases (DNMT), generating 5-methyl cytosine 
(5mC) (Figure 1.5) (Santos et al., 2005). The DNMTs known to date are DNMT1, 
DNMT1b, DNMT1o, DNMT1p, DNMT2, DNMT3A, DNMT3b with its isoforms, and 
DNMT3L (Robertson, 2002). Methylation can be de novo (when CpG dinucleotides on 
both DNA strands are unmethylated) or maintenance (when CpG dinucleotides on one 
strand are methylated). DNMT1 has de novo as well as maintenance methyltransferase 
activity, and DNMT3A and DNMT3b are powerful de novo methyltransferases (Costello 
and Plass, 2001). The important roles of this post-synthetic modification through 
DNMTs have been shown using several mouse experiments.  For instance, it is vital for 
mammalian embryonic development as shown by early lethality in mice that lack DNA 
methyltransferases (Dnmts) (Li et al., 1992; Okano et al., 1999). Dnmt-null mice have  
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Figure 1.4: Interaction between DNA methylation, RNA and histone modification in 
heritable silencing. Histone deacetylation and other modifications, especially the 
methylation of lysine 9 within histone H3 (H3-K9) residues located in the histone tails, 
cause chromatin condensation and block transcriptional initiation. Histone modification 
can also attract DNA methyltransferases to begin cytosine methylation, which in turn can 
reinforce histone modification patterns conducive to silencing. Study with yeast and 
plants clearly showed the involvement of RNA interference in the establishment of 
heterochromatin states and silencing. RNA triggering of heritable quiescence might 
therefore also be involved in higher animals. (Mazzio and Soliman., 2012). 
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Figure 1.5: DNA methylation. A family of DNA methyltransferases (DNMTs) 
catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to the 
fifth carbon of cytosine residue to form 5-methylcytosine (mC). (a) DNMT3A and 
DNMT3B are the de novo DNMTs and transfer methyl groups (red) onto newly 
synthesized DNA. (b) DNMT1 is the maintenance DNMT which preserves DNA 
methylation pattern during replication. During semiconservative replication, the 
parental DNA strand retains the original DNA methylation pattern (gray). 
Subsequently, DNMT1 associates at the replication focus and precisely replicates 
the original DNA methylation pattern by adding methyl groups (red) onto the 
newly formed daughter strand (blue) (Moore et al., 2013). 
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reduced DNA methylation levels, but the exact reasons for death during development are 
unclear. It has been suggested in two research papers that methylation of cytosine 
residues in the context of CpG dinucleotides could serve as an epigenetic mark in ver-
tebrates (Holliday and Pugh, 1975; Riggs, 1975). Both papers proposed that sequences 
could be methylated de novo, that methylation can be inherited through somatic cell 
divisions by a mechanism involving an enzyme that recognizes hemimethylated CpG 
palindromes, that the presence of methyl groups could be interpreted by DNA-binding 
proteins and that DNA methylation directly silences genes. Although several of these 
key tenets turned out to be correct, the correlations between DNA methylation and gene 
silencing have proved to be challenging to resolve (Jones, 2012).  
 
Understanding the roles of DNA methylation requires consideration of the distribution 
of methylation across the genome. More than half of the genes in vertebrate genomes 
have short CpG-rich regions known as CpG islands and the rest of the genome is 
depleted for CpGs (Jones, 2012).  
 
DNA methylation mostly occurs on cytosines that precede a guanine nucleotide or CpG 
sites. There is confirmation of non-CpG methylation in undifferentiated  mouse and 
human embryonic, however these methylations are lost in develop tissues (Ramsahoye 
et al., 2000). Evidence suggests that DNA methylation of the gene body is correlated 
with a higher level of gene expression in dividing cells (Hellman and Chess, 2007; Ball 
et al., 2009; Aran et al., 2011), but in slowly dividing and nondividing cells such as the 
brain cells, gene body methylation is not correlated with increased gene expression 
(Aran et al., 2011; Guo et al., 2011, b; Xie et al., 2012). More thorough examination of 
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the murine frontal cortex has recently revealed that although the bulk of methylation 
occurs within CpG sites, there is a significant percentage of methylated non-CpG sites 
(Xie et al., 2012). However, the role of non-CpG methylation is still unclear.  
 
1.5.2 DNA Methylation and CpG Promoter 
In mammals, methylation is confined to CpG dinucleotides, which are hugely depleted 
from the genome except at short genomic regions called CpG islands, which are usually 
located at gene promoters (Ioshikhes and Zhang, 2000). CpG islands are stretches of 
DNA roughly 1000 base pairs long that have a higher CpG density than the rest of the 
genome but often are not methylated (Bird et al, 1985). Roughly about 70% of CpG 
islands reside within gene promoters (Saxonov et al, 2006). In particular, the CpG 
islands are often imbedded in promoter of housekeeping genes (Gardiner-Garden and 
Frommer, 1987). CpG islands within the promoter regions are highly conserved between 
mice and humans (Illingworth et al., 2010). 
 
The location and preservation of CpG islands throughout evolution define that these 
particular regions possess a functional importance. Impairment of transcription factor 
binding, recruitment of repressive methyl-binding proteins, and stabilizing the silence 
gene expression are the effect of methylation within that CpG islands (Klose and Bird, 
2006).Few mechanisms have been suggested to account for transcriptional repression by 
DNA methylation. One of the mechanisms involves direct interference with the binding 
of specific transcription factors to their recognition sites in their respective promoters 
(Das and Singal, 2004). Several transcription factors, including AP-2, c-Myc/Myn, the 
cyclic AMP-dependent activator CREB, E2F, and NFkB, recognize sequences that 
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contain CpG residues and binding of each of these TF has been shown to be inhibited by 
methylation (Singal and Ginder, 1999; Tate and Bird, 1993).  The local concentration of 
CpGs within the promoter could affect the strength of gene repression. Indeed, it is 
established that methylation of CpG-rich promoters is incompatible with gene activity, 
yet no conclusive picture has emerged for promoters containing low amounts of CpGs 
(Boyes and Bird, 1992; Hsieh, 1994). Most CpG island promoters remain unmethylated 
even in cell types that do not express the gene (Bird, 2002). Nevertheless, changes in 
DNA methylation linked to tissue-specific gene expression have been seen sporadically 
on CpG-rich promoters (Song et al., 2005).  
 
1.5.3 DNA Methylation and Cancer Development 
There was one study postulated that epigenetic changes could influence cancer 
progenitor cell formation, cancer progression, and formation of stage-specific metastatic 
cancer (Byler et al., 2014). As compared with normal cells, the malignant cells represent 
major disruptions in their DNA methylation patterns (Baylin and Herman, 2000). It 
involves both histone modifications and DNA methylation at specific CpG residues. 
Many oncogenes including ras and src, become activated by mutations during 
carcinogenesis (hypermethylation) (Frew et al., 2008; Sarkar and Faller, 2011; Mataga 
et al., 2012; Sarkar et al., 2013). Conversely, many tumor suppressor genes including 
both cell-cycle inhibitors and pro-apoptotic genes are silenced by methylation of CpG 
islands in their promoter sites (hypomethylation) (Heerboth et al., 2014). There are 
several examples of silenced tumor suppressor genes in cancers, for instance, p21, p16, 
p27, differentiation marker RARβ2, and imprinted pro-apoptotic gene ARHI (in breast 
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and ovarian cancer) (Monier, 1990). Up to date, there are numerous genes have been 
found to undergo hypermethylation in cancer (Table 1.1).  
 
Many tumors show some kind of hypermethylation of one or more genes (Table 1). 
Lung cancer is the cancer type that has been mostly studied and more than 40 genes 
were found to have several degrees of alteration in DNA methylation patterns. Among 
the various genes studied, the usually hypermethylated genes include RAR_, RASSF1A, 
CDNK2A, CHD13, and APC (Tsou et al., 2002). Hypermethylation lead to loss of 
expression of a variety of important genes for the development of breast cancer such as 
steroid receptor genes, cell adhesion genes, and inhibitors of matrix metalloproteinases 
(Yang et al., 2001). Genes that commonly associated with hypermethylation in breast 
cancer are the p16NK4A, estrogen receptor (ER) alpha, the progesterone receptor (PR), 
BRCA1, GSTP1, TIMP-3, and E-cadherin.  
 
Besides, many leukemia and other hematologic diseases are associated with 
hypermethylation. Several genes, such as the calcitonin gene, p15INK4B, 
p21Cip1/Waf1, the ER gene, SDC4, MDR, and others were seen to be hypermethylated 
in a variety of hematologic cancers (Leone et al., 2002). 65% of myelodysplastic 
syndromes were found to have hypermethylation in calcitonin  
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Gene Role In Tumour 
Development 
Site of Tumour References 
APC  
 
Deranged regulation of 
cell proliferation, cell 
migration, cell adhesion, 
cytoskeletal 
reorganization 
and chromosomal 
stability 
Breast 
Lung 
Esophageal 
Virmani et al., 
2001 
Kawakami et al., 
2000 
BRCA1  Implicated in DNA repair 
and transcription 
activation 
Breast 
Ovarian 
Kawakami et al., 
2005 
Chan et al., 2002 
CDKN2A/p16  Cyclin-dependent kinase 
inhibitor 
Gastrointestinal 
Head and neck 
Herman et al., 1995 
Sanchez-Cespedes 
et al., 2000 
DAPK1  Calcium/calmodulin-
dependent enzyme that 
phosphorylates serine / 
threonine residues on 
protein; Suppression of 
apoptosis 
Lung Harden et al., 2003 
E-cadherin  
 
Increasing proliferation, 
invasion, and/or 
metastasis 
Breast 
Thyroid 
Gastric 
Graff et al., 1995 
Graff et al., 1998 
Waki et al., 2002 
ER  Hormone resistance Breast 
Prostate 
Yang et al., 2001 
Li et al., 2000 
GSTP1  
 
Loss of detoxification of 
active metabolites of 
several carcinogens 
Prostate 
Breast 
Renal 
Lee et al., 1994 
Esteller et al., 1998 
Esteller et al., 1998 
 
 
 
 
Table 1.1: Several genes commonly methylated in human cancer and their role in 
tumor development. Abbreviations: APC, adenomatous polyposis coli; BRCA1, 
breast cancer 1; CDKN2A/p16, cyclin-dependent kinase 2A; DAPK1, death-
associated protein kinase 1; ER, estrogen receptor; GSTP1, glutathione S-
transferase Pi 1(Das and Singal, 2004). 
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gene and p15. Additionally, detection of p15 methylation at diagnosis was associated 
with lower survival rate (Leone et al., 2002). Hypomethylation is the second type of 
methylation irregularity that is seen in a wide variety of malignancies (Feinberg and 
Vogelstein, 1983; Kim et al., 1994). Progressive increase in the grade of malignancy can 
be seen in a number of cancers such as breast, cervical, and brain and all of these cancer 
types are closely related to global hypomethylation (Ehrlich., 2002). Long interspersed 
nuclear elements are the most plentiful mobile DNAs or retrotransposons in the human 
genome. Hypomethylation of these mobile DNAs causes transcriptional activation as has 
been found in many types of cancer including urinary bladder cancer (Jürgens et al., 
1996) and it also causes disruption of expression of the adjacent genes as well (Das and 
Singal., 2004). 
 
1.6 Methylating and demethylating agents 
DNA methylation, histone modification, nucleosome remodeling, and RNA-mediated 
targeting has been deeply studied over the last few years as these events are involved in 
the regulation of biological processes that are essential to the genesis of cancer (Dawson 
and Kouzarides, 2012). Epigenetic modifications are appealing to be as therapeutic 
targets in cancer due to their dynamic nature and potential reversibility (Einav Nili et al., 
2008). Various compounds that alter DNA methylation patterns are recently being 
examined as single agents or in combinations with other drugs in clinical settings, such 
as budesonide, a DNA hypermethylating agent and 5-Azacytidine, a DNA 
hypomethylating agent (Einav Nili et al., 2008).  
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1.6.1 Budesonide  
Budesonide (Figure 1.6) is a hypermethylating agent and known synthetic glucocorticoid 
with clinically significant anti-inflammatory effects (Tao et al., 2002; Orta et al., 2010).  
It is a glucocorticoid used to control mild-to-moderate persistent asthma (Pereira et al., 
2007). Budesonide has been shown to prevent the formation of lung adenomas and 
adenocarcinomas in mice when administered either by inhalation or in the diet 
(Wattenberg et al., 1997; Estensen et al., 2004). As a chemopreventive agent, 
budesonide appears to reduce both the growth rate of tumors and the progression of 
adenomas to adenocarcinomas through hypermethylation of genes (Pereira et al., 2007). 
When budesonide was administered into mice with lung tumors, very rapidly, within 
days, the methylation of tumor DNA was increased and resulting in DNA that was no 
longer hypomethylated (Pereira et al., 2007).  
 
1.6.2 5-Azacytidine 
Even though 5-azacytidine (Figure 1.7) has been known to have cytotoxic an effect on 
cancer cells since 1968, its mechanism of action was discovered more recently 
(Kaminskas et al., 2005). 5-Azacytidine is a cytidine analog, with a nitrogen atom in the 
place of carbon 5. In molecular level, it is phosphorylated, incorporated into DNA 
during replication and recognized by DNMT1. Thus, the normal reaction involving the 
transfer of a methyl group starts to take place (Heerboth et al., 2014). There will be a 
formation of an irreversible DNMT1–aza linkage due to the nitrogen group in the fifth 
position which triggers the degradation of the enzyme and leads to widespread 
reductions in methylation (hypomethylation) (Santi et al., 1984; Momparler et al., 
2005). Rapidly dividing cancer cells are more susceptible to its effects as aza are more  
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Figure 1.6: The chemical structure of budesonide. Budesonide is a 
synthetic anti-inflammatory glucocorticoid which acts as a 
hypermethylating agent. 
(http://www.drugfuture.com/pharmacopoeia/usp32/pub/data/v32270/us
p32nf27s0_m10458.html) 
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Figure 1.7: Molecular structure of 5-Azacytidine. 5-Azacytidine is a 
pyrimidine ring analogue in which the ring carbon 5 is replaced by 
nitrogen (Kaminskas et al., 2005). 
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1.7 Rationale of the study 
The function of CK was shown to be essential for the biosynthesis of 
phosphatidylcholine. ckα and ckβ enzymes have been implicated in pathogenesis of  
cancer, muscular dystrophy and bone deformities, thus they become a potential target for 
therapy (Wu and Vance, 2010). However, the exact mechanisms or involvement of CK 
in disease development are still remaining unclear. The ckα has been reported to be 
overexpressed in 70% of human tumors. The pharmacological inhibition of ckα has been 
proposed as a novel anti-tumoral strategy (Gallego-Ortega et al., 2009).   
 
A known epigenetics mechanism, DNA methylation can control gene expression by 
modulating the activity of a promoter either by increasing or reducing the promoter 
activity. Even though there are many previous studies that demonstrated the association 
between CK and cancer pathogenesis, up to date, the effects of hypomethylation and 
hypermethylation on the CK promoters are not yet explored.  Budesonide 
(hypermethylating agent) and 5 Azacytidine (demethylating agent) are known to alter 
the pattern of gene expression (Santi et al., 1984; Momparler et al., 2005; Orta et al., 
2010). Hypomethylation is demonstrated to stimulate gene expression, while 
hypermethylation causes gene repression.  
 
Cis-acting transcriptional regulatory elements of a promoter contain recognition sites for 
trans-acting DNA-binding transcription factors, which function either to enhance or 
repress transcription (Cooper, 2000; Maston et al., 2006). The presences of multiple 
regulatory elements within promoters are essential to control the gene regulation, which 
exponentially increases the potential number of unique expression patterns (Maston et 
